AU2017234676A1 - Carbonic anhydrase IX targeting agents and methods - Google Patents
Carbonic anhydrase IX targeting agents and methods Download PDFInfo
- Publication number
- AU2017234676A1 AU2017234676A1 AU2017234676A AU2017234676A AU2017234676A1 AU 2017234676 A1 AU2017234676 A1 AU 2017234676A1 AU 2017234676 A AU2017234676 A AU 2017234676A AU 2017234676 A AU2017234676 A AU 2017234676A AU 2017234676 A1 AU2017234676 A1 AU 2017234676A1
- Authority
- AU
- Australia
- Prior art keywords
- conjugate
- pharmaceutically acceptable
- acceptable salt
- alkyl
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OPLYPVQSMPYGAO-UHFFFAOYSA-N CCCN(CC(N)=O)CC(Nc(cc1)ccc1S(N)(=O)=O)=O Chemical compound CCCN(CC(N)=O)CC(Nc(cc1)ccc1S(N)(=O)=O)=O OPLYPVQSMPYGAO-UHFFFAOYSA-N 0.000 description 1
- WIFHOWZPFAECCM-UHFFFAOYSA-O CN(C)c(cc1O2)ccc1C(c(c(C(O)=O)c1)ccc1C(NCCOCCOCCOCCOCCC(Nc1cc(NC(Nc(cc3)ccc3S(N)(=O)=O)=O)ccc1)=O)=O)=C(C=C1)C2=CC1=[N+](C)C Chemical compound CN(C)c(cc1O2)ccc1C(c(c(C(O)=O)c1)ccc1C(NCCOCCOCCOCCOCCC(Nc1cc(NC(Nc(cc3)ccc3S(N)(=O)=O)=O)ccc1)=O)=O)=C(C=C1)C2=CC1=[N+](C)C WIFHOWZPFAECCM-UHFFFAOYSA-O 0.000 description 1
- MRJGIRXDKWIULL-NSCUHMNNSA-N CNC(/C(/N)=C\N)=O Chemical compound CNC(/C(/N)=C\N)=O MRJGIRXDKWIULL-NSCUHMNNSA-N 0.000 description 1
- WIXXORUTQRZZIH-UHFFFAOYSA-N NC(CN(CCN(CC=O)CC(Nc(cc1)ccc1S(N)(=O)=O)=O)CC(O)=O)=O Chemical compound NC(CN(CCN(CC=O)CC(Nc(cc1)ccc1S(N)(=O)=O)=O)CC(O)=O)=O WIXXORUTQRZZIH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309264P | 2016-03-16 | 2016-03-16 | |
| US201662309268P | 2016-03-16 | 2016-03-16 | |
| US62/309,268 | 2016-03-16 | ||
| US62/309,264 | 2016-03-16 | ||
| PCT/US2017/022785 WO2017161170A1 (en) | 2016-03-16 | 2017-03-16 | Carbonic anhydrase ix targeting agents and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017234676A1 true AU2017234676A1 (en) | 2018-09-20 |
Family
ID=59852046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017234676A Abandoned AU2017234676A1 (en) | 2016-03-16 | 2017-03-16 | Carbonic anhydrase IX targeting agents and methods |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11925696B2 (https=) |
| EP (1) | EP3429575A4 (https=) |
| JP (1) | JP7027325B2 (https=) |
| AU (1) | AU2017234676A1 (https=) |
| CA (1) | CA3017214A1 (https=) |
| WO (1) | WO2017161170A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3017214A1 (en) | 2016-03-16 | 2017-09-21 | Purdue Research Foundation | Carbonic anhydrase ix targeting agents and methods |
| CA3017211A1 (en) * | 2016-03-16 | 2017-09-21 | Endocyte, Inc. | Carbonic anhydrase ix inhibitor conjugates and uses thereof |
| WO2020045638A1 (ja) * | 2018-08-30 | 2020-03-05 | 日本メジフィジックス株式会社 | 放射性イミダゾチアジアゾール誘導体化合物 |
| AU2024266164A1 (en) * | 2023-05-02 | 2025-10-30 | Rayzebio, Inc. | Radiopharmaceutical compositions targeting carbonic anhydrase ix and uses thereof |
| CN120943769A (zh) * | 2025-08-08 | 2025-11-14 | 浙江普罗亭健康科技有限公司 | 可应用于质谱流式检测的金属离子螯合结构及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2260875T3 (da) * | 2002-05-06 | 2014-06-30 | Endocyte Inc | Folatreceptor-targetede billeddannelsesmidler |
| EP1594962B1 (en) * | 2003-01-31 | 2014-08-27 | Promega Corporation | Covalent tethering of functional groups to proteins |
| WO2006076463A2 (en) * | 2005-01-12 | 2006-07-20 | Amgen Inc. | Kinase-directed, activity-based probes |
| AU2006279304A1 (en) | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Multi-drug ligand conjugates |
| US20090043099A1 (en) | 2006-03-17 | 2009-02-12 | The Burnham Institute | Methods and compositions for derepression of IAP-inhibited caspase |
| WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| EP4464384A3 (en) | 2007-08-17 | 2025-01-08 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| CA2711678A1 (en) | 2008-01-09 | 2009-07-16 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of carbonic anhydrase ix |
| WO2010087994A2 (en) * | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| CN101596433B (zh) | 2009-07-15 | 2011-07-06 | 中国科学院工程热物理研究所 | U形返料器的冷却式隔板 |
| FR2951449B1 (fr) * | 2009-10-15 | 2011-11-25 | Commissariat Energie Atomique | Procede de fonctionnalisation de molecules biologiques |
| US8547533B2 (en) * | 2009-12-28 | 2013-10-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Composite probes and use thereof in super resolution methods |
| US20130053392A1 (en) | 2010-02-12 | 2013-02-28 | Peter Ebbesen | Carbonic anhydrase inhibitors |
| JP5544239B2 (ja) * | 2010-07-29 | 2014-07-09 | 富士フイルム株式会社 | 重合性組成物 |
| AU2012253502C1 (en) * | 2011-05-09 | 2017-12-14 | Visen Medical, Inc. | Carbonic anhydrase targeting agents and methods of using same |
| AU2012296937B2 (en) | 2011-08-17 | 2017-10-12 | Merck & Cie | Folate conjugates of albumin-binding entities |
| US20140249315A1 (en) | 2013-03-01 | 2014-09-04 | Endocyte, Inc. | Processes for preparing tubulysins |
| WO2015113760A1 (en) * | 2014-01-28 | 2015-08-06 | Tube Pharmaceuticals Gmbh | Cytotoxic tubulysin compounds for conjugation |
| US9771380B2 (en) * | 2014-06-09 | 2017-09-26 | University Of Oregon | Gold nanoparticles and methods of making and using gold nanoparticles |
| CA3017214A1 (en) | 2016-03-16 | 2017-09-21 | Purdue Research Foundation | Carbonic anhydrase ix targeting agents and methods |
| CA3017211A1 (en) * | 2016-03-16 | 2017-09-21 | Endocyte, Inc. | Carbonic anhydrase ix inhibitor conjugates and uses thereof |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
-
2017
- 2017-03-16 CA CA3017214A patent/CA3017214A1/en active Pending
- 2017-03-16 EP EP17767563.4A patent/EP3429575A4/en not_active Withdrawn
- 2017-03-16 WO PCT/US2017/022785 patent/WO2017161170A1/en not_active Ceased
- 2017-03-16 JP JP2018549202A patent/JP7027325B2/ja not_active Expired - Fee Related
- 2017-03-16 AU AU2017234676A patent/AU2017234676A1/en not_active Abandoned
- 2017-03-16 US US16/085,393 patent/US11925696B2/en active Active
-
2024
- 2024-02-08 US US18/436,484 patent/US20240316224A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20240316224A1 (en) | 2024-09-26 |
| EP3429575A1 (en) | 2019-01-23 |
| JP2019512511A (ja) | 2019-05-16 |
| JP7027325B2 (ja) | 2022-03-01 |
| US20190083663A1 (en) | 2019-03-21 |
| WO2017161170A1 (en) | 2017-09-21 |
| US11925696B2 (en) | 2024-03-12 |
| EP3429575A4 (en) | 2019-10-23 |
| CA3017214A1 (en) | 2017-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260048157A1 (en) | Fibroblast activation protein (fap)-targeted imaging and therapy | |
| US11883498B2 (en) | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof | |
| US20240316224A1 (en) | Carbonic anhydrase ix targeting agents and methods | |
| EP3672615B1 (en) | Fbsa-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers | |
| US10857234B2 (en) | Carbonic anhydrase IX inhibitor conjugates and uses thereof | |
| HK40016572A (en) | Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof | |
| HK40016572B (en) | Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof | |
| HK40016594B (en) | Fibroblast activation protein (fap)-targeted imaging and therapy | |
| HK40016594A (en) | Fibroblast activation protein (fap)-targeted imaging and therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |